CEO Anna Söderlund comments:
"I want to thank all investors who have chosen to subscribe in the issuance. We are pleased with the outcome and look forward to continuing our work in completing our products and launching them on the market. In 2018, we will begin production set-up and continue our CE marking process. We see great potential with Calmark and are sure that our products will make a difference for the smallest patients.
Subscription and allocation
Issuance was subscribed at approximately SEK 23 thousand, which corresponds to a subscription rate of approximately 100.4%. During the issuance, 5,000,000 B shares and 3,000,000 warrants of series to 1 B were issued. Calmark is thus issued at approximately SEK 23 thousand before issuance costs, which amounts to approximately SEK 1.8 thousand. Sales notes are scheduled to be issued today, June 14, 2018.
The first day of trading and liquidity guarantee
The first day of trading in Calmark's B shares and warrants of series TO 1 B on Spotlight is planned for July 6, 2018. B shares will be traded under the name "CALMA" and the ISIN code of the B-shares is SE0011116524. Warrants of series TO 1 B will be traded under the name "CALMA TO 1 B" and ISIN code of the warrants is SE0011204890. Prior to the planned listing, Calmark subsequently appointed the stock brokerage firm Sedermera Fondkommission to act as liquidity guarantor for the company's series B shares. Liquidity guarantee will commence with the company's planned listing on Spotlight. Subsequently, the Sedermera Fondkommission (brokerage) will fulfill its mandate as liquidity guarantor to continuously place trade posts on each purchase and sales page in the order book for Calmark's B shares and ensure that it is kept as a predetermined spread in the share. The purpose of the liquidity guarantee is to promote good liquidity and ensure a low spread between the buying and selling rate in the current trade.
The number of shares and share capital
When Calmark's issuance of units are registered at the Swedish Companies Registration Office, the total number of shares will increase to a total of 10,404,500 (of which 540,450 are A shares) and the share capital will amount to SEK 1,040,450. In addition, there are 3 million outstanding TO 1 B-series warrants.
Conditions for the warrants in summary
The newly-issued warrants of TO 1 B-series (ISIN code: SE0011204890) are expected to be traded on Spotlight as of July 6, 2018. The possession of one (1) warrants of TO 1 B-series gives entitlement to the subscription of one (1) newly issued B-share at a price of SEK 5.40. The subscription of B shares with the support of warrants may take place from May 23, 2019 to June 13, 2019.
Sedermera Fondkommission (brokerage) is Calmark's financial advisor in connection with the issuance of units and the planned listing on Spotlight.
Calmark is obliged to publish this information under the EU Market Abuse Regulation. The information was submitted by the above contact person for publication on Thursday, June 14, 2018.
For more information about the issuance of units and the planned listing on Spotlight, please contact:
Sedermera Fondkommission (brokerage)
Phone: +46 40-615 14 10
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Phone: +46 70 213 25 35
Calmark Sweden AB is a medical technology company engaged in the research and development of point-of-care diagnostic products intended for newborns. The company is developing a point-of-care (POC) analysis method that can provide decision-making support in the care of newborns more quickly and easily than existing methods. As a first step, Calmark will offer three important point-of-care tests for an infant's first week of life. The triple diagnostics is expected to be ready for production during the fourth quarter of 2019, with the launch planned for areas of Europe and Asia in 2020. Calmark intends to generate revenue through the sale of the reader and disposable products. Our goal is to become a leading player in POC diagnostics for newborns and, in the long term, to supply all relevant tests for the newborn's first period of life. Read more about Calmark at www.calmark.se.